Advanced

Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? : Role of beta2-adrenergic agonists

Fuster, Gemma; Busquets, Sílvia; Ametller, Elisabet; Olivan, Mireia; Almendro, Vanessa; Fontes Oliveira, Cibely LU ; Figueras, Maite; López-Soriano, Francisco J and Argilés, Josep M (2007) In Cancer Research 67(13). p.9-6512
Abstract

Implantation of the Yoshida AH-130 ascites hepatoma to rats resulted in a decrease in muscle weight 7 days after the inoculation of the tumor. These changes were associated with increases in the mRNA content for both peroxisome proliferator-activated receptor (PPAR) gamma and PPAR delta in skeletal muscle. The increase in gene expression for these transcription factors was related to increases in the expression of several genes involved in fatty acid transport, activation, and oxidation. Tumor burden also resulted in increases in PPAR gamma coactivator-1 alpha gene expression and pyruvate dehydrogenase kinase 4. All these changes in lipid metabolism genes suggest that a metabolic shift occurs in skeletal muscle of tumor-bearing rats... (More)

Implantation of the Yoshida AH-130 ascites hepatoma to rats resulted in a decrease in muscle weight 7 days after the inoculation of the tumor. These changes were associated with increases in the mRNA content for both peroxisome proliferator-activated receptor (PPAR) gamma and PPAR delta in skeletal muscle. The increase in gene expression for these transcription factors was related to increases in the expression of several genes involved in fatty acid transport, activation, and oxidation. Tumor burden also resulted in increases in PPAR gamma coactivator-1 alpha gene expression and pyruvate dehydrogenase kinase 4. All these changes in lipid metabolism genes suggest that a metabolic shift occurs in skeletal muscle of tumor-bearing rats toward a more oxidative phenotype. Formoterol treatment to tumor-bearing rats resulted in an amelioration of all the changes observed as a result of tumor burden. Administration of this beta(2)-adrenergic agonist also resulted in a decrease in mRNA content of muscle PPAR alpha, PPAR delta, and PPAR gamma, as well as in mRNA levels of many of the genes involved in both lipid and mitochondrial metabolism. All these results suggest an involvement of the different PPARs as transcription factors related with muscle wasting and also indicate that a possible mode of action of the anticachectic compound formoterol may involve a normalization of the levels of these transcription factors.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
keywords
Adrenergic beta-Agonists, Animals, Body Weight, Cachexia, Fatty Acids, Gene Expression Regulation, Neoplastic, Lipid Metabolism, Male, Muscle, Skeletal, Muscular Atrophy, Neoplasms, Experimental, Peroxisome Proliferator-Activated Receptors, Rats, Rats, Wistar, Transcription, Genetic, Journal Article, Research Support, Non-U.S. Gov't
in
Cancer Research
volume
67
issue
13
pages
9 - 6512
publisher
American Association for Cancer Research Inc.
external identifiers
  • scopus:34447130860
ISSN
0008-5472
DOI
10.1158/0008-5472.CAN-07-0231
language
English
LU publication?
no
id
4d1709dc-78d0-4b8a-b508-cd472b11f6ea
date added to LUP
2017-02-28 16:21:40
date last changed
2017-04-23 04:58:40
@article{4d1709dc-78d0-4b8a-b508-cd472b11f6ea,
  abstract     = {<p>Implantation of the Yoshida AH-130 ascites hepatoma to rats resulted in a decrease in muscle weight 7 days after the inoculation of the tumor. These changes were associated with increases in the mRNA content for both peroxisome proliferator-activated receptor (PPAR) gamma and PPAR delta in skeletal muscle. The increase in gene expression for these transcription factors was related to increases in the expression of several genes involved in fatty acid transport, activation, and oxidation. Tumor burden also resulted in increases in PPAR gamma coactivator-1 alpha gene expression and pyruvate dehydrogenase kinase 4. All these changes in lipid metabolism genes suggest that a metabolic shift occurs in skeletal muscle of tumor-bearing rats toward a more oxidative phenotype. Formoterol treatment to tumor-bearing rats resulted in an amelioration of all the changes observed as a result of tumor burden. Administration of this beta(2)-adrenergic agonist also resulted in a decrease in mRNA content of muscle PPAR alpha, PPAR delta, and PPAR gamma, as well as in mRNA levels of many of the genes involved in both lipid and mitochondrial metabolism. All these results suggest an involvement of the different PPARs as transcription factors related with muscle wasting and also indicate that a possible mode of action of the anticachectic compound formoterol may involve a normalization of the levels of these transcription factors.</p>},
  author       = {Fuster, Gemma and Busquets, Sílvia and Ametller, Elisabet and Olivan, Mireia and Almendro, Vanessa and Fontes Oliveira, Cibely and Figueras, Maite and López-Soriano, Francisco J and Argilés, Josep M},
  issn         = {0008-5472},
  keyword      = {Adrenergic beta-Agonists,Animals,Body Weight,Cachexia,Fatty Acids,Gene Expression Regulation, Neoplastic,Lipid Metabolism,Male,Muscle, Skeletal,Muscular Atrophy,Neoplasms, Experimental,Peroxisome Proliferator-Activated Receptors,Rats,Rats, Wistar,Transcription, Genetic,Journal Article,Research Support, Non-U.S. Gov't},
  language     = {eng},
  month        = {07},
  number       = {13},
  pages        = {9--6512},
  publisher    = {American Association for Cancer Research Inc.},
  series       = {Cancer Research},
  title        = {Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? : Role of beta2-adrenergic agonists},
  url          = {http://dx.doi.org/10.1158/0008-5472.CAN-07-0231},
  volume       = {67},
  year         = {2007},
}